Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes
暂无分享,去创建一个
Ah Ram Lee | Jeong‐Hoon Lee | Dong-Sik Kim | Mehrangiz Dezhbord | Eun-Sook Park | Kyun-Hwan Kim | Jong Chul Kim | Soree Park | Juhee Won | J. Cho | N. Kim | Jae Jin Shin | S. Choo | Chang Hyun Ahn
[1] Ah Ram Lee,et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. , 2019, Journal of hepatology.
[2] Xuesen Zhao,et al. Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance , 2019, bioRxiv.
[3] Haitao Guo,et al. Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine‐resistant HBV isolate , 2019, Antiviral research.
[4] J. H. Kim. 2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What's Different? , 2018, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
[5] B. McMahon,et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.
[6] T. Luedde,et al. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. , 2017, Journal of hepatology.
[7] H. Chan,et al. Tenofovir Alafenamide: A Review in Chronic Hepatitis B , 2017, Drugs.
[8] John F. Flaherty,et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment , 2017, Journal of viral hepatitis.
[9] Zhi-hui Xu,et al. Increased Occurrence of Mutant rtI233V of HBV in Patients Receiving Adefovir Therapy , 2015, Antiviral therapy.
[10] M. Kumar,et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.
[11] Gérard Krause,et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.
[12] Ah Ram Lee,et al. Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance , 2015, PloS one.
[13] H. Lee,et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial , 2015, Gut.
[14] Jianming Hu,et al. Unveiling the roles of HBV polymerase for new antiviral strategies. , 2015, Future virology.
[15] H. Lee,et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial , 2015, Gut.
[16] K. Kitrinos,et al. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] Young Youn Cho,et al. Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B , 2014, Antimicrobial Agents and Chemotherapy.
[18] W. Choe,et al. The Impact of the Hepatitis B Virus Polymerase rtA181T Mutation on Replication and Drug Resistance Is Potentially Affected by Overlapping Changes in Surface Gene , 2014, Journal of Virology.
[19] P. Marcellin,et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load , 2013, Hepatology.
[20] John F. Flaherty,et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.
[21] B. Seong,et al. Discovery and Development of Anti-HBV Agents and Their Resistance , 2010, Molecules.
[22] Ronald E. Rose,et al. Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy , 2009, Hepatology.
[23] M. Ghany,et al. Antiviral resistance and hepatitis B therapy , 2009, Hepatology.
[24] Seahee Kim,et al. DDX3 DEAD-Box RNA Helicase Inhibits Hepatitis B Virus Reverse Transcription by Incorporation into Nucleocapsids , 2009, Journal of Virology.
[25] Jianming Hu,et al. Reverse Transcriptase- and RNA Packaging Signal-Dependent Incorporation of APOBEC3G into Hepatitis B Virus Nucleocapsids , 2008, Journal of Virology.
[26] N. Warner,et al. The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro , 2007, Antimicrobial Agents and Chemotherapy.
[27] Angeline Bartholomeusz,et al. HBV drug resistance: mechanisms, detection and interpretation. , 2006, Journal of hepatology.
[28] J. Echevarría,et al. Hepatitis B virus genetic diversity , 2006, Journal of medical virology.
[29] D. Rowlands,et al. Introduction of replication-competent hepatitis C virus transcripts using a tetracycline-regulable baculovirus delivery system. , 2004, The Journal of general virology.
[30] Michael D. Miller,et al. The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.
[31] Deborah Chavez,et al. Antiviral Effect and Virus-Host Interactions in Response to Alpha Interferon, Gamma Interferon, Poly(I)-Poly(C), Tumor Necrosis Factor Alpha, and Ribavirin in Hepatitis C Virus Subgenomic Replicons , 2003, Journal of Virology.
[32] Zheng-hong Yuan,et al. A Single Amino Acid in the Reverse Transcriptase Domain of Hepatitis B Virus Affects Virus Replication Efficiency , 2001, Journal of Virology.
[33] Ding‐Shinn Chen,et al. Hepatitis B Virus Infection , 2007 .
[34] J. Wands,et al. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.
[35] C. Seeger,et al. Hepadnavirus assembly and reverse transcription require a multi‐component chaperone complex which is incorporated into nucleocapsids , 1997, The EMBO journal.
[36] J. Wands,et al. Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication , 1991, Journal of virology.
[37] P. Seglen. Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. , 1973, Experimental cell research.